Objectives: The aim of the study was to examine resistance mechanisms associated with an AmpC phenotype in Norwegian clinical isolates of Escherichia coli.
Introduction
AmpC b-lactamases represent a group of clinically important b-lactamases that are naturally produced by a variety of Gram-negative bacteria. When overexpressed, they confer clinical resistance to penicillins and cephalosporins, except cefpirome and cefepime. In combination with porin loss, they may also mediate resistance to carbapenems. 1, 2 AmpC enzymes are, with a few exceptions, not inhibited by b-lactamase inhibitors. 3 The chromosomal ampC gene of Escherichia coli has a weak promoter and a transcriptional attenuator. 4 E. coli strains containing the wild-type gene produce a low basal level of the enzyme and are susceptible to cephalosporins, but mutations in the promoter or in the attenuator regions can lead to hyperproduction of the enzyme and cephalosporin resistance. The most common mutations change the promoter to resemble the E. coli consensus promoter or weaken the attenuator. 5 -13 Plasmid-mediated ampC genes were first detected in 1988.
14 They are thought to have originated from their chromosomal location in organisms such as Enterobacter spp., Citrobacter freundii, Morganella morganii, Hafnia alvei and Aeromonas spp. 15 These genes are of special interest, as plasmids are able to spread efficiently between species. They have been classified into six genetic clusters, which can be identified by a family-specific multiplex PCR. 16 The bla CMY-2 gene is the most prevalent and has been reported worldwide. Interestingly, bla CMY-2 is found in many different plasmid backbones, suggesting that it can be mobilized as a part of a smaller transferable fragment. 17 Recent data have shown that plasmid-mediated bla CMY-2 genes in E. coli and Salmonella enterica are linked to ISEcp1-like elements, which probably mobilize bla CMY-2 as part of a composite transposon. 17 The purpose of this study was to examine Norwegian clinical isolates of E. coli with an AmpC phenotype for genetic alterations leading to increased expression of the chromosomal ampC gene, as well as acquired plasmid-mediated ampC genes and their genetic support.
Materials and methods

Bacterial strains and antimicrobial susceptibility testing
From March 2003 to December 2005, the Norwegian Reference Centre for Detection of Antimicrobial Resistance (K-res) received 106 clinical isolates of E. coli, with reduced susceptibility to thirdgeneration cephalosporins without clavulanic acid synergy. Initial antimicrobial susceptibility testing and interpretations were performed in each laboratory by their routine methods in agreement with the Norwegian Working Group on Antibiotics guidelines and the recommendations of the European Committee for Antimicrobial Susceptibility Testing. 18 The isolates were examined at K-res using the following panel of b-lactam Etests (AB Biodisk, Solna, Sweden), according to the manufacturer's instructions: ampicillin (AMP), amoxicillin/clavulanic acid (AMC), piperacillin (PIP), piperacillin/tazobactam (TZP), cefoxitin (FOX), cefpodoxime (CPD), cefotaxime (CTX), ceftazidime (CAZ), cefepime (FEP), aztreonam (ATM), imipenem (IMP) and meropenem (MEM). Final bacterial identification was performed at K-res using the Vitek2 ID-GNB system (bioMérieux, Marcy l'É toile, France) or API ID32E (bioMérieux) and/or 16S rDNA-sequence typing in cases of low discrimination, as described previously.
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Vitek2 ASTN023 (bioMérieux) was used to determine susceptibility to non-b-lactam antibiotics. Tests for synergy between cephalosporins and clavulanic acid were performed by ESBL Etests (AB Biodisk), including cefotaxime/clavulanic acid, ceftazidime/clavulanic acid and cefepime/ clavulanic acid. The Etest selection criteria for further molecular analysis were: (i) reduced susceptibility to third-generation cephalosporins (cefpodoxime, cefotaxime and ceftazidime MICs !4 mg/L) without clavulanic acid synergy; (ii) cefoxitin MIC . 16 mg/L; (iii) susceptibility or intermediate susceptibility to cefepime; and (iv) susceptibility to carbapenems. A total of 22 out of 106 isolates isolated at 12 laboratories fulfilled the selection criteria (urine n ¼ 14, blood n ¼ 4 and others n ¼ 4) and were selected for molecular analysis. Control strains are presented in Table S1 [available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. The rifampicin-resistant E. coli A53 (J53-2) was used as a recipient strain in filter-mating experiments. Antimicrobial susceptibility testing of control strains was performed by Vitek II AST-029 (bioMérieux).
Isoelectric focusing (IEF) of b-lactamases
Analytic IEF of crude cell extracts was performed in precast Ampholine PAGplate polyacrylamide gels with a pH range of 3.5 -9.5 (GE Healthcare, Oslo, Norway), using a Multiphor II Apparatus (GE Healthcare). b-Lactamase activity was detected by staining the gels with nitrocefin solution (0.5 g/L). The isoelectric points ( pIs) of the studied b-lactamases were determined by comparison with reference b-lactamases bla TEM-1 ( pI 5.4) and bla SHV-1 ( pI 7.6), as well as with naturally coloured IEF Protein Standards pI 4.45 -9.6 (Bio-Rad Laboratories, Hemel Hempstead, UK).
PCR amplification and DNA sequencing
Bacterial DNA extraction and consensus PCRs for the most prevalent Ambler class A b-lactamase genes (bla TEM , bla SHV and bla CTX-M ) were performed, as described previously. 19 A multiplex PCR covering the six families of ampC genes (ACC, CIT, DHA, EBC, FOX and MOX) 16 and a specific bla CMY PCR were performed. bla CMY PCR products were sequenced. Chromosomal ampC promoter mutations and insertions were examined by PCR and sequencing. Genetic linkage between the insertion sequence ISEcp1 and bla CMY was examined by an ISEcp1-bla CMY linkage PCR. PCR primers are listed in Table 1 . PCR amplification and bidirectional DNA sequencing were performed as described previously. 19 
Molecular typing by PFGE
Possible genomic relatedness of strains was analysed by PFGE following a standard protocol. 20 Briefly, agarose plugs with extracted DNAs were digested with XbaI (New England BioLabs, Beverly, USA). Agarose plugs were stored in 50 mM thiourea (Sigma-Aldrich Co., St Louis, MO, USA) before XbaI digestion to inhibit DNase activity. PFGE gels were run by multidirectional gel electrophoresis using the Chef-DR w III System (Bio-Rad Laboratories). Electrophoresis was run at 128C with a pulse time of 1-20 s at 6 V/cm on a 1208 angle in 0.5Â TBE buffer for 21 h. DNA relatedness was interpreted by the criteria of Tenover et al.
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RNA isolation and cDNA synthesis
Bacterial isolates were cultured overnight in Luria-Bertani (LB) broth at 378C and diluted 1:300 in fresh LB broth and grown to a mid-log growth phase. Total RNA was isolated using RNeasy kit (Qiagen, Oslo, Norway) and RNAprotect Bacteria Reagent (Qiagen), according to the manufacturer's instructions. Genomic DNA was removed by RNase-free DNase (Qiagen). Purified RNA was stored in RNase-free water at 2808C. RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA). RNA integrity was checked in a FlashGel System (CAMBREX, ME, USA). cDNA syntheses were performed in triplicate using 400 ng of RNA per 20 mL reaction according to the manufacturer's instructions (High capacity cDNA Reverse Transcription Kit, Applied Biosystems, Oslo, Norway).
Real-time qRT -PCR
Real-time qRT-PCR experiments were performed using qPCR Mastermix Plus (Eurogenetec). Synthesized cDNAs were diluted 1:10 and amplified in triplicate. Amplifications were also performed on cDNA synthesis run without reverse transcriptase to confirm the absence of DNA in the RNA samples. The ampC target gene was normalized against the reference gene glyceraldehyde 3-phosphate dehydrogenase (gapA) 13, 22 using Q-Gene. 23, 24 The ampC mRNA mean normalized expression level was calibrated as fold differences using the mean normalized expression level of ATCC 25922 as 1.0. Standard errors were calculated for the fold differences according to the standard errors for the ampC mRNA mean normalized expression levels.
Plasmid analyses and hybridization
Filter-mating experiments were performed on LB agar plates. The donor/recipient ratio was 1:1. Filter-mating plates were incubated at 378C for 16 h. E. coli transconjugants were selected on LB agar containing cefoxitin 32 mg/L and rifampicin 100 mg/L. An S1 nuclease plasmid assay was used for the detection and size determination of circular DNA. 25 Briefly, the procedure includes lysis of bacterial cells embedded in agarose plugs, 20 digestion with 50 U of S1 nuclease (Promega, Madison, WI, USA) at 378C for 25 min, and finally PFGE at 148C with a pulse time of 1-25 s at 6 V/cm on a 1208 angle in 0.5Â TBE buffer for 20 h. Southern transfer of S1-nuclease-digested DNAs from PFGE gels to positively charged nylon membranes (Roche Applied Science, Penzberg, Germany) was performed by vacuum blotting (Vacugene XL system, GE Healthcare). DNA was fixed to the nylon membrane by UV cross-linking. A bla CMY-2 probe was constructed by labelling a bla CMY-2 PCR product using the PCR DIG Probe Synthesis Kit (Roche Applied Science). The labelled PCR product was purified by agarose gel electrophoresis followed by extraction using the QIAquick Gel Extraction Kit (Qiagen). Hybridization was carried out at 688C, and detection was performed using the DIG Luminescent Detection Kit (Roche Applied Science). All protocols were performed according to the manufacturer's instructions.
Computer analyses of DNA sequences
Analyses and alignments of DNA sequences were performed using the DNAStar software package (DNAStar Inc., Madison, WI, USA). Nucleotide sequences were compared with sequences in the NCBI GenBank database (http://www.ncbi.nlm.nih.gov/Genbank/index. html) using the Basic Local Alignment Search Tool (BLAST) BLASTn. (Table 2 ), corresponding to the alkaline profile of AmpC b-lactamases (discussed subsequently). In addition, other b-lactamase bands with lower pIs were also detected in some isolates. These included bands with pIs around 5.5, corresponding to bla TEM-1 b-lactamases (Table 2) . Importantly, control strains A2-6 and A2-7, expressing bla TEM-1 or bla SHV-1 , respectively, had bands at pI 5.4 or 7.6 exclusively, as expected.
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The presence of acquired AmpC b-lactamase genes was examined by multiplex PCR for ampC-type genes and showed bla CIT in 10 of 22 isolates (Table 2) . A bla CMY -specific PCR and DNA sequence analysis revealed bla CMY-7 (n ¼ 1) and bla CMY-2 (n ¼ 9) ( Table 2) . bla TEM , bla SHV and bla CTX-M consensus PCRs identified nine bla TEM -positive strains (Table 2) . Seven isolates had both bla TEM and bla CMY genes. All strains were negative for bla SHV and bla CTX-M .
All 22 isolates had a b-lactamase band with a pI of 9.0 -9.2 on nitrocefin-stained IEF gels, but 12 of these were negative by ampC multiplex PCR (Table 2) , suggesting increased expression of the chromosomal ampC gene. PCR and sequencing of the ampC control regions ( promoters and attenuators) were performed, and the sequences were compared with the ampC control region of E. coli K12 strain (GenBank accession number NC_000913) by nucleotide alignment (Figure 1b) . All ampC multiplex PCR-negative strains with an AmpC phenotype had mutations or insertions in their control regions, which could explain hyperproduction of the chromosomal AmpC enzyme (Figure 1b) . Three different mechanisms for increased expression of chromosomal ampC genes were identified. (i) A major group of nine strains had mutations at positions 288
and þ58 (C!T). The 242 (C!T) mutation seems critical for resistance in this context as similar promoters without this mutation are susceptible to cephalosporins (Figure 1b) . (ii) Two strains (K8-2 and K25-65) did not have the same mutations as the major group. These showed different single nucleotide insertions in the spacer regions between the 235 and 210 boxes, shifting the length of the spacer region to the optimal 17 bp (Figure 1b) . In addition, both these strains showed mutations in the attenuator region. (iii) One isolate (K15-8) had a large insertion in the chromosomal ampC promoter region between the 235 and 210 boxes in position 217/218 (Figure 1a and b) . Sequence analyses and nucleotide BLAST searches demonstrated that the insertion element was identical to the putative IS element ISEc10 from E. coli CFT073 (GenBank accession number AE014075). The nucleotide sequence alignment of target sequences for ISEc10 insertions showed that the ISEc10 element generates a 5 or 6 bp direct repeat of the target gene region (Figure 2) . A direct repeat is also found for the ampC promoter target sequence (Figure 2 ), suggesting that ISEc10 behaves as an IS element during transfer. The target sequence for ISEc10 does not seem to be conserved (Figure 2) . The most conserved position is immediately 5 0 of the insertion element, cytosine (6/8)/pyrimidine (7/8) (Figure 2) . Importantly, although our control E. coli strains (n ¼ 18) also had several mutations in their ampC control regions compared with E. coli K12, none of these had the 242 mutation, a 1 nt spacer region insertion, critical mutations in their attenuator regions or IS elements inserted in their promoter regions (Figure 1b ).
Increased expression of chromosomal ampC genes by mutations or insertions in the gene control regions
Isolates with alterations in the ampC gene control region were analysed for the expression of the chromosomal ampC gene by real-time qRT -PCR. All strains showed highly increased expression of the ampC gene compared with the control strain E. coli ATCC 25922 ranging from 27-to 380-fold (Table 2) . Importantly, clinical control strains showed about similar expression of the ampC gene as E. coli ATCC 25922.
Acquired bla CMY genes
The 10 bla CMY -positive E. coli isolates were recovered in seven different laboratories and were clonally unrelated, thus indicating the spread of a common bla CMY -containing plasmid. Filtermating experiments between the 10 bla CMY -positive E. coli isolates and an E. coli recipient strain resulted in exconjugants from all donors, suggesting that bla CMY genes were located on plasmids (data not shown). The plasmid contents of all the 22 E. coli isolates were analysed by PFGE of S1-nuclease-digested total DNAs. Plasmid profiling and subsequent hybridization with a DIG-labelled bla CMY-2 probe showed that the bla CMY genes were located on plasmids in the majority (K2-67, K5-20, K13-18, K20-72, K26-7, K26-8 and K26-35) of the strains; see Figure S1 (a and b) [available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/)]. The size of the plasmids ranged from~87 to 282 kb. K5-41 and K5-63 DNAs supported bla CMY hybridization to both plasmid-located and chromosomally located bands and a chromosomally located band only, respectively [lanes 4 and 5, Figure S1(b) ]. This may suggest that bla CMY could be located on a mobile genetic element on the chromosome. The result for strain K26-21 could not be interpreted due to high DNase activity. Importantly, none of the ampC multiplex PCR-negative strains had bands that hybridized to the bla CMY-2 probe [ Figure S1 (b) and data not shown].
bla CMY genes are linked to ISEcp1-like elements
It has previously been reported that b-lactamase genes of the bla CTX-M and bla CMY types can be genetically linked to ISEcp1. 27 -37 ISEcp1 has experimentally been shown to mediate transfer of bla CTX-M genes by using surrogate IRR sequences. 33, 37 A PCR with a forward primer in the transposase gene of the ISEcp1 element and a reverse primer in the bla CMY genes was performed. All strains with bla CMY genes produced an amplicon of the expected size (data not shown), suggesting that all bla CMY genes were linked to an ISEcp1-like element. PCR analysis using primers specific for C. freundii-related genes blc, sugE and dsbC gave PCR products of the anticipated size in accordance with those reported by Kang et al., 17 categorizing them as either type 1 or type 2. Sequencing a subset of these amplicons revealed 100% identity to previous reports. 17 
Discussion
This is the first molecular study of Norwegian clinical E. coli isolates with an AmpC phenotype. Two different mechanisms explaining AmpC hyperproduction were detected in the 22 strains. Hyperproduction of the chromosomal AmpC enzyme due to mutations (n ¼ 11) or an ISEc10 insertion (n ¼ 1) in the control region of the chromosomal ampC gene was found in 12 strains. An ISEcp1-like-bla CMY element was detected in 10 strains. PFGE analyses and examination of bla CMY -containing plasmids revealed genetically unrelated strains, suggesting that the emergence of Norwegian AmpC E. coli strains is not due to clonal dissemination or spread of a common plasmid between strains. It should be noted that the ACC-1 b-lactamase would escape our phenotypic screening due to susceptibility to cefoxitin.
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Nine of the strains with increased expression of the chromosomal ampC had identical mutations at positions 288, 282, 242, 218, 21 and þ58. Similar mutations have previously been described in clinical E. coli strains. 6,9 -11 Two of the ampC multiplex PCR-negative strains showed mutations in the attenuator regions and single nucleotide insertions in the spacer regions between the 235 and the 210 boxes, shifting the spacer region to the optimal 17 bp. Previous observations of the ampC gene control region suggest that insertion of a single base pair between the 235 and the 210 boxes or mutations of the attenuator region are by themselves sufficient for increased transcription of the ampC gene. 4, 9, 40 An insertion of the putative IS element ISEc10 in the chromosomal ampC promoter region was found in one isolate. ISEc10 belongs to the IS21 family of IS elements and harbours two open reading frames, encoding a putative transposase and a putative ATP-binding protein (http://www-is.biotoul.fr/, 7 May 2008, date last accessed). The ISEc10 element probably enhances transcription of the chromosomal ampC gene by inserting a new strong 235 box (TTGACG), located in the ISEc10 IRR, 17 bp upstream of the endogenous 210 box in the ampC promoter. This may account for the 54-fold increased expression of AmpC and resistant phenotype observed in this strain (Table 2) . It has been shown that insertion of IS elements can increase the expression of downstream genes, 41 and upstream insertion of IS911, IS10 and IS2 has been suggested to mediate increased transcription of the ampC gene in previous studies. 9, 42 All strains with mutations or insertions in the chromosomal ampC gene control region had at least 27-fold increased expression of the ampC gene compared with E. coli ATCC 25922. These results correlate well with previous results from Canadian E. coli clinical isolates. 13 Our results show that although six of our isolates (K2-68, K4-30, K4-37, K9-66, K22-31 and K25-19) have similar mutations in the sequenced ampC gene control region, their increase of expression varies from 27-to 203-fold. This may indicate that strain-specific factors other than the nucleotide composition of the gene control region contribute to the level of AmpC production in the cell. We do not see a direct relationship between the level of increased ampC mRNA expression in the cephalosporin-resistant isolates and MICs of cephalosporins (Table 2) , supporting the finding of Tracz et al. 13 that other strain-specific factors seem to play a role in determining the MIC of cefoxitin.
The finding of bla CMY-2 as the most commonly acquired ampC gene is consistent with observations in other countries. 9,43 -46 S1-nuclease analysis and bla CMY-2 hybridization revealed plasmid heterogeneity, suggesting that the distribution of bla CMY genes in Norwegian clinical isolates of E. coli is not due to the transfer of the same R-plasmid between different strains. Both bla CMY-2 and bla CMY-7 genes were genetically linked to ISEcp1-like elements. This is in accordance with observations showing ISEcp1-like elements linked to bla CMY as well as bla CTX-M . 27 -37 Experimental evidence for ISEcp1-mediated mobilization of bla CTX-M genes has recently been provided. 33, 37 The DNA sequence of the ISEcp1-bla CMY region included the genes blc and sugE immediately downstream, indicating that the genetic context of bla CMY-2 is remarkably conserved in strains from the USA, Taiwan and now Norway. 17, 38 We have no information about the possible contribution from other resistance mechanisms such as porin defects or mutations within the chromosomal ampC genes, 47, 48 but our observations may suggest that increased expression of the endogenous chromosomal ampC gene is as efficient as plasmid-acquired ampC when it comes to clinically relevant resistance levels to extendedspectrum cephalosporins in E. coli. The diagnostic implication of this finding is that no phenotypic test will discriminate clearly between the two mechanisms mediating the AmpC phenotype. 48, 49 We will thus have to rely on genetic methods for their identification.
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In conclusion, the present study demonstrates that AmpC resistance in Norwegian E. coli is due to expression of bla CMY from an acquired ISEcp1-like-bla CMY element or alterations in the ampC control region causing increased expression of the endogenous ampC gene. 
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